| Date | Title | | | 04/13/18 | Natera to Present Successful Results at AACR from Bladder and Colon Cancer Studies| Performance Data for Treatment Monitoring, Recurrence Monitoring, and Staging at Diagnosis
SAN CARLOS, Calif., April 13, 2018 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, will present data demonstrating the ability of Signatera™ (Research Use Only) to monitor treatment response, detect minimal residual disease, and identify disease recurrence in bladder and colorectal cancers at the AACR (American Association ... |
| | | 04/10/18 | Natera To Present New Data at ACMG Annual Meeting| Study results demonstrate value of SNP-based non-invasive prenatal testing, expanded carrier screening, and embryo and miscarriage tissue testing across various genetic conditions
SAN CARLOS, Calif., April 10, 2018 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, will present new data that demonstrate the value of its unique single nucleotide polymorphism (SNP)-based technology and the benefits of expanded carrier... |
| | | 04/09/18 | Natera Appoints Paul R. Billings, M.D., Ph.D., as Chief Medical Officer| Leading authority on genomics and diagnostics in medical practice will help Natera's efforts in advancing individualized genomic medicine
SAN CARLOS, Calif., April 9, 2018 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA (cfDNA), has appointed Paul R. Billings, M.D., Ph.D., as Chief Medical Officer and Senior Vice-President of Medical Affairs to help lead its efforts across reproductive health, oncology, and new em... |
| | | 03/13/18 | Natera Reports Fourth Quarter and Fiscal Year 2017 Financial Results| SAN CARLOS, Calif., March 13, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the fourth quarter and fiscal year ended December 31, 2017 and provided an update on recent business progress.
Recent Accomplishments & Highlights
Signed $50.0 million next-generation sequencing agreement with QIAGEN, Inc, with $40.0 million cash r... |
| | | 03/12/18 | QIAGEN and Natera partner to develop cutting-edge genetic testing assays for use on QIAGEN's GeneReader NGS System| HILDEN, Germany, and SAN CARLOS, Calif., March 12, 2018 /PRNewswire/ -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a world leader in providing Sample to Insight molecular solutions, and Natera, Inc. (NASDAQ: NTRA), a leading developer of next-generation sequencing (NGS) assays that include non-invasive prenatal genetic testing and the analysis of circulating tumor DNA, today announced a partnership to develop cutting-edge, cell-free DNA assays for use on QIAGEN's GeneReader NGS Sys... |
| | | 03/07/18 | Natera Inc. Announces Fourth Quarter and Fiscal 2017 Earnings Conference Call| Natera Also Presenting at the 38th Annual Cowen Healthcare Conference
SAN CARLOS, Calif., March 7, 2018 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its fourth quarter and year ended December 31, 2017 after the market close on March 13, 2018. Natera will host a conference call and webcast at 2 p.m. PT (5 p.m. ET) to discuss its financial results, business... |
| | | 03/05/18 | Natera's Genetic Tests Now Fully Integrated into Yale New Haven Health's Epic EMR System| SAN CARLOS, Calif., March 5, 2018 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that Yale New Haven Health has fully integrated the company's Panorama® non-invasive prenatal test (NIPT) and Horizon™ carrier screening test into its Epic electronic medical record (EMR) platform, making it easier for physicians to order and receive prenatal genetic testing information.
... |
| | | 01/29/18 | Natera To Feature Expanded Panorama® Non-Invasive Prenatal Test, Now Validated for Twin Pregnancies, at SMFM Annual Meeting| SAN CARLOS, Calif., Jan. 29, 2018 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, will feature its recently expanded Panorama® non-invasive prenatal test (NIPT), which is now validated for screening twin pregnancies, at the Society for Maternal-Fetal Medicine (SMFM) Annual Meeting in Dallas, Jan. 29 to Feb. 3, 2018 (booth No. 161).
Panorama® is the first NIPT that can screen twin p... |
| | | 01/08/18 | Natera To Webcast Live Presentation at the 36th Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2018| SAN CARLOS, Calif., Jan. 8, 2018 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will webcast a live presentation at the 36th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Thursday, Jan. 11, 2018 at 9:00 a.m. Pacific Time.
Natera CEO Matthew Rabinowitz will provide an overview of the company and its latest devel... |
| |
|
